Healthcare provider profile · identity verified

Jeevarathna Subramanian, MD

Internal Medicine · BENICIA, CA · NPI 1790752186

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	407	117
Omeprazole	Omeprazole	305	101
Lisinopril	Lisinopril	288	77
Rosuvastatin Calcium	Rosuvastatin Calcium	281	92
Amlodipine Besylate	Amlodipine Besylate	268	81
Levothyroxine Sodium	Levothyroxine Sodium	231	52
Gabapentin	Gabapentin	191	51
Metformin Hcl Er	Metformin Hcl	179	62
Metoprolol Succinate	Metoprolol Succinate	172	49
Losartan Potassium	Losartan Potassium	154	41
Tamsulosin Hcl	Tamsulosin Hcl	132	45
Famotidine	Famotidine	128	46
Fluticasone Propionate	Fluticasone Propionate	127	49
Diclofenac Sodium	Diclofenac Sodium	122	40
Ozempic	Semaglutide	121	19
Hydrochlorothiazide	Hydrochlorothiazide	119	35
Metformin Hcl	Metformin Hcl	108	32
Simvastatin	Simvastatin	108	33
Albuterol Sulfate Hfa	Albuterol Sulfate	106	34
Jardiance	Empagliflozin	102	31
Alendronate Sodium	Alendronate Sodium	89	23
Sertraline Hcl	Sertraline Hcl	85	27
Ventolin Hfa	Albuterol Sulfate	83	17
Lorazepam	Lorazepam	76	17
Pantoprazole Sodium	Pantoprazole Sodium	73	25
Eliquis	Apixaban	69	17
Duloxetine Hcl	Duloxetine Hcl	65	18
Clonazepam	Clonazepam	64	suppressed
Atenolol	Atenolol	61	17
Buspirone Hcl	Buspirone Hcl	61	11
Furosemide	Furosemide	61	21
Mirtazapine	Mirtazapine	59	15
Trazodone Hcl	Trazodone Hcl	55	16
Allopurinol	Allopurinol	54	16
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	54	suppressed
Celecoxib	Celecoxib	50	17
Escitalopram Oxalate	Escitalopram Oxalate	50	16
Spironolactone	Spironolactone	50	13
Ipratropium Bromide	Ipratropium Bromide	49	15
Valsartan	Valsartan	47	17
Trulicity	Dulaglutide	40	15
Meloxicam	Meloxicam	39	16
Amitriptyline Hcl	Amitriptyline Hcl	37	11
Donepezil Hcl	Donepezil Hcl	36	suppressed
Pravastatin Sodium	Pravastatin Sodium	36	11
Ezetimibe	Ezetimibe	35	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	34	13
Alprazolam	Alprazolam	33	suppressed
Tramadol Hcl	Tramadol Hcl	33	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	32	14
Venlafaxine Hcl Er	Venlafaxine Hcl	32	suppressed
Bupropion Xl	Bupropion Hcl	31	12
Potassium Chloride	Potassium Chloride	30	11
Prednisone	Prednisone	30	25
Ketoconazole	Ketoconazole	28	13
Lidocaine	Lidocaine	27	14
Mounjaro	Tirzepatide	27	suppressed
Estradiol	Estradiol	26	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	26	11
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	25	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	25	suppressed
Citalopram Hbr	Citalopram Hydrobromide	24	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	24	suppressed
Finasteride	Finasteride	23	suppressed
Topiramate	Topiramate	23	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	20	suppressed
Baclofen	Baclofen	20	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	20	suppressed
Nystatin	Nystatin	20	11
Terazosin Hcl	Terazosin Hcl	20	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	18	suppressed
Ibuprofen	Ibuprofen	18	suppressed
Myrbetriq	Mirabegron	18	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	18	18
Valacyclovir	Valacyclovir Hcl	18	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	18	suppressed
Carvedilol	Carvedilol	17	suppressed
Labetalol Hcl	Labetalol Hcl	17	suppressed
Rybelsus	Semaglutide	17	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	16	13
Glipizide Er	Glipizide	16	suppressed
Oxycodone Hcl	Oxycodone Hcl	16	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	16	suppressed
Synthroid	Levothyroxine Sodium	16	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	16	suppressed
Aripiprazole	Aripiprazole	15	suppressed
Hydralazine Hcl	Hydralazine Hcl	15	suppressed
Pregabalin	Pregabalin	15	suppressed
Breo Ellipta	Fluticasone/Vilanterol	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Epinephrine	Epinephrine	14	suppressed
Fluocinolone Acetonide Oil	Fluocinolone Acetonide Oil	14	suppressed
Klor-Con M20	Potassium Chloride	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Methocarbamol	Methocarbamol	14	suppressed
Vyvanse	Lisdexamfetamine Dimesylate	14	suppressed
Amiloride Hcl	Amiloride Hcl	13	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	13	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	13	suppressed
Diazepam	Diazepam	13	suppressed
Farxiga	Dapagliflozin Propanediol	13	suppressed
Invokana	Canagliflozin	13	suppressed
Montelukast Sodium	Montelukast Sodium	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	12	suppressed
Hydrocortisone	Hydrocortisone	12	suppressed
Tizanidine Hcl	Tizanidine Hcl	12	suppressed
Arnuity Ellipta	Fluticasone Furoate	11	suppressed
Nexium	Esomeprazole Magnesium	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error